Compare ALDX & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALDX | STIM |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.9M | 120.4M |
| IPO Year | 2014 | 2018 |
| Metric | ALDX | STIM |
|---|---|---|
| Price | $1.59 | $1.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $5.50 | $3.00 |
| AVG Volume (30 Days) | 1.7M | ★ 2.2M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 40.43 | ★ 57.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $52,776,000.00 |
| Revenue This Year | N/A | $11.10 |
| Revenue Next Year | N/A | $11.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $0.80 |
| 52 Week High | $6.18 | $4.84 |
| Indicator | ALDX | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 36.89 | 56.46 |
| Support Level | $1.49 | $1.21 |
| Resistance Level | $1.91 | $2.22 |
| Average True Range (ATR) | 0.14 | 0.23 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 9.58 | 37.93 |
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.